SER
Serina Therapeutics, Inc. · Healthcare
2.00
7.21%(-0.15)
Market OpenLast Updated: — ET
52W L: $1.2252W H: $7.92
$2.00
CHG+0.47 (+30.39%)
H$3.30
L$1.22
VOL37M
SER (1h)
Serina Therapeutics, Inc. · Healthcare
– Novel lipid nanoparticles entirely built on the POZ Platform that overcome the PEG immunogenicity dilemma – Design & synthesis of novel ionizable POZ lipids to replace current ionizable lipids for the delivery of a multitude of oligonucleotide payloads – HUNTSVILLE, AL, April 07, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, announced that Serina Therapeutics Chief Development Officer, Randall Moreadith, MD, PhD, will be presenting today at the 5th LNP Formulation & Process Development Summit in Boston, MA. Entitled "Novel Lipid Nanoparticles Built Entirely on a POZ Platform", Dr. Moreadith will present data demonstrating the POZ-lipid in Serina's platform failed to elicit an antibody response to the polymer in a vaccine format in the rat.
HUNTSVILLE, April 02, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today reported that the NYSE American LLC ("NYSE American") has accepted the Company's business plan to regain compliance with the continued listing standards set forth in Sections 1003(a)(i) or 1003(a)(ii) of the NYSE American Company Guide.
- FDA Grants IND Clearance for SER-252- SER-252 Phase 1b Trial Initiated- Closed Private Placement Financing of up to $30 Million HUNTSVILLE, March 25, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform drug optimization technology, today reported its financial results for the full year ended December 31, 2025 and provided recent business highlights.
HUNTSVILLE, AL, March 24, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, announced that Steve Ledger, Chief Executive Officer, will present in a fireside chat at the 38th Annual Roth Conference in Dana Point, CA on March 24, 2026, at 11:30 a.m. PST.
U.S. stock futures declined on Friday following Thursday's declines. Futures of the major benchmark indices were lower.
Serina Therapeutics Inc. surged 39.45% in after-hours trading Wednesday following a $15 million private placement announcement.
Moreadith Randall
officer: Chief Scientific Officer
6,500 SH @ $0.06
2026-03-23
Moreadith Randall
officer: Chief Scientific Officer
6,500 SH @ $0.06
2026-03-23
Moreadith Randall
officer: Chief Scientific Officer
6,500 SH @ $2.86
2026-03-23
Moreadith Randall
officer: Chief Scientific Officer
39,000 SH @ $0.06
2026-03-19
Moreadith Randall
officer: Chief Scientific Officer
39,000 SH @ $0.06
2026-03-19
Moreadith Randall
officer: Chief Scientific Officer
39,000 SH @ $2.50
2026-03-19
Moreadith Randall
officer: Chief Scientific Officer
69,000 SH @ $2.76
2026-02-03
Tenjarla Srini
officer: SVP, CMC & Formulation
69,000 SH @ $2.76
2026-02-03